Enclomiphene does raise testosterone levels, and clinical trials show it can more than double total testosterone in men starting from low baselines. In one study, men with secondary hypogonadism who started around 253 ng/dL reached an average of 586 ng/dL after six weeks on the highest dose, putting them squarely in the normal range. That said, enclomiphene is not FDA-approved, and the story behind why reveals some important nuances about what “works” really means.
How Enclomiphene Raises Testosterone
Enclomiphene works by tricking your brain into producing more testosterone on its own. Normally, the brain monitors estrogen levels and uses that signal to decide how much stimulating hormone to send to the testes. Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary gland, so the brain “thinks” estrogen is low and ramps up production of two key hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH tells the testes to make more testosterone. FSH drives sperm production.
This is fundamentally different from injecting or applying testosterone directly. When you take exogenous testosterone, your brain detects the rising levels and shuts down its own signaling, which is why testosterone replacement therapy suppresses sperm production and can cause testicular shrinkage. Enclomiphene does the opposite: it keeps the brain’s natural signaling pathway active and amplifies it.
What the Clinical Trial Numbers Show
A pharmacodynamic study tested three doses of enclomiphene (6.25 mg, 12.5 mg, and 25 mg daily) against topical testosterone gel over six weeks in men with secondary hypogonadism. The results were dose-dependent. Men on 6.25 mg averaged 391 ng/dL, those on 12.5 mg averaged 426 ng/dL, and the 25 mg group reached 586 ng/dL. The topical testosterone group landed at 546 ng/dL. Statistically, there was no significant difference between the highest enclomiphene dose and topical testosterone.
The speed of response is notable too. Significant increases in total testosterone appeared within just two weeks of starting treatment in an earlier phase II trial. That’s a relatively fast onset for an oral medication working through indirect hormonal signaling rather than delivering testosterone directly.
The baseline numbers matter for context. Men in these trials were starting with testosterone levels around 250 to 270 ng/dL, well below the normal range of roughly 300 to 1,000 ng/dL. Enclomiphene brought most of them into the mid-normal range. If you’re starting from a higher baseline, the absolute increase will likely look different.
The Fertility Advantage Over TRT
This is where enclomiphene has the clearest practical edge. In randomized controlled trials comparing enclomiphene to topical testosterone, both treatments raised testosterone levels. But only enclomiphene increased FSH and LH while preserving or increasing sperm counts. Topical testosterone, by contrast, tends to suppress sperm production, sometimes to zero.
For men who want higher testosterone but also want to maintain fertility (or who are actively trying to conceive), this distinction is significant. It’s also the reason enclomiphene has attracted attention in younger men and in the growing market of men’s health clinics. Research in obese men with hypogonadism specifically confirmed that oral enclomiphene raised testosterone while preserving sperm counts, a combination exogenous testosterone simply cannot offer.
How It Differs From Regular Clomiphene
Clomiphene citrate (sold as Clomid) has been used off-label for male hypogonadism for years. It contains two mirror-image molecules: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). These two isomers do very different things. Enclomiphene blocks estrogen receptors, which is the desired effect. Zuclomiphene actually activates estrogen receptors, partially working against the purpose of the drug.
Zuclomiphene also has a much longer half-life, meaning it accumulates in the body over time. This buildup of an estrogen-mimicking compound is thought to contribute to some of clomiphene’s side effects, including mood changes and visual disturbances. Enclomiphene, as the isolated trans isomer, avoids this accumulation. In theory, this gives it a cleaner side effect profile, though large-scale safety comparisons between the two remain limited.
Why It’s Not FDA-Approved
Despite the testosterone data, the FDA has not approved enclomiphene. The drug has been under review since 2007, and the FDA rejected it because raising testosterone numbers alone wasn’t considered sufficient proof that the drug actually helps patients. The agency also rejected normalization of LH levels and improvements in quality-of-life scores as acceptable endpoints.
This is an important point for anyone evaluating whether enclomiphene “works.” It clearly raises testosterone on a blood test. What hasn’t been proven to the FDA’s satisfaction is that those higher numbers translate into meaningful improvements in symptoms like low energy, reduced sex drive, or loss of muscle mass. Testosterone levels and how someone feels don’t always move in lockstep, and the FDA wanted stronger evidence of real-world benefit.
Because it lacks approval, enclomiphene is currently available through compounding pharmacies and some telehealth clinics rather than as a standard prescription drug. This means manufacturing quality and dosing consistency can vary depending on the source.
What We Know About Safety
Phase III safety studies have been conducted with treatment periods lasting up to 52 weeks. These trials assessed bone mineral density, lean body mass, eye health (including slit lamp and visual acuity exams), and standard lab work. The inclusion of eye exams reflects a known concern with clomiphene, which can cause visual disturbances in some users.
Because enclomiphene removes the zuclomiphene isomer that accumulates and mimics estrogen, it’s expected to carry fewer side effects than traditional clomiphene. However, the absence of FDA approval also means the long-term safety data hasn’t gone through the full regulatory review process. Most of what’s available comes from clinical trial populations studied for weeks to months, with limited data beyond one year of continuous use.
Dosing in Practice
Clinical trials have tested daily doses of 6.25 mg, 12.5 mg, and 25 mg. The testosterone response scales with dose: the 25 mg group saw the strongest results, with average levels reaching the mid-500s to low 600s ng/dL. The lower doses still raised testosterone meaningfully but to a lesser degree. Many clinics prescribing enclomiphene start at 12.5 mg or 25 mg daily, though protocols vary since there’s no FDA-approved dosing guideline to standardize practice.
One practical consideration is that enclomiphene is taken orally, which is simpler than the daily topical application or regular injections required by most testosterone replacement options. For men who want to avoid the routine of gels, patches, or needles, this is a genuine convenience factor.